Quoin CEO, Dr. Michael Myers, said, "2022 as a whole was a year of significant progress for Quoin and the fourth quarter continued that trend of operational execution across a number of important metrics. We were very pleased to announce the dosing of the first patient in our ongoing double blinded, placebo controlled study in Netherton Syndrome patients. This study has continued to recruit and dose patients since then and overall interest in participation in the study remains very high."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on QNRX:
- Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and Full Year 2022 Financial Results
- Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET
- Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
- Quoin Pharmaceuticals 4.95M ADS secondary priced at $1.00
- Quoin Pharmaceuticals files to sell $10M of ordinary shares